Hot Features
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phas... BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.37 | -10.2777777778 | 3.6 | 3.95 | 3.18 | 44196 | 3.5864019 | DR |
| 4 | 0.09 | 2.86624203822 | 3.14 | 3.95 | 2.52 | 114934 | 2.85010006 | DR |
| 12 | 0.53 | 19.6296296296 | 2.7 | 3.95 | 2.15 | 52493 | 2.78350804 | DR |
| 26 | -0.05 | -1.5243902439 | 3.28 | 3.95 | 2.15 | 33633 | 2.83377277 | DR |
| 52 | -1.42 | -30.5376344086 | 4.65 | 6.59 | 2.15 | 46832 | 3.97194804 | DR |
| 156 | 1.56 | 93.4131736527 | 1.67 | 7.7699 | 0.0815 | 920807 | 0.84379076 | DR |
| 260 | 0.33 | 11.3793103448 | 2.9 | 7.7699 | 0.0815 | 712070 | 1.09920305 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.